• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical outcomes of presbyopia correction with the latest techniques of presbyLASIK: a systematic review.最新的老视矫正技术行准分子激光老视眼手术的临床疗效:系统评价。
Eye (Lond). 2023 Mar;37(4):587-596. doi: 10.1038/s41433-022-02175-3. Epub 2022 Jul 21.
2
Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on people with long-term respiratory conditions.个体层面的干预措施以减少个人接触室外空气污染及其对长期呼吸系统疾病患者的影响。
Cochrane Database Syst Rev. 2021 Aug 9;8(8):CD013441. doi: 10.1002/14651858.CD013441.pub2.
3
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
4
Electronic cigarettes for smoking cessation.电子烟戒烟。
Cochrane Database Syst Rev. 2021 Sep 14;9(9):CD010216. doi: 10.1002/14651858.CD010216.pub6.
5
Electronic cigarettes for smoking cessation.电子烟戒烟。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD010216. doi: 10.1002/14651858.CD010216.pub7.
6
Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients.非 ICU 住院患者预防谵妄的非药物干预措施。
Cochrane Database Syst Rev. 2021 Nov 26;11(11):CD013307. doi: 10.1002/14651858.CD013307.pub3.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
8
Electronic cigarettes for smoking cessation.用于戒烟的电子烟。
Cochrane Database Syst Rev. 2025 Jan 29;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub9.
9
Reminiscence therapy for dementia.痴呆症的回忆疗法
Cochrane Database Syst Rev. 2018 Mar 1;3(3):CD001120. doi: 10.1002/14651858.CD001120.pub3.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

引用本文的文献

1
Surgical interventions for presbyopia.老花眼的手术干预措施。
Cochrane Database Syst Rev. 2025 Apr 14;4(4):CD015711. doi: 10.1002/14651858.CD015711.pub2.
2
Contrast Sensitivity and Stereopsis Outcomes Following LASIK Presbyopia Correction Based on the Corneal Aberration Modulation or Corneal Multifocality Induction Methods: A Systematic Review.基于角膜像差调制或角膜多焦点诱导方法的LASIK老视矫正术后的对比敏感度和立体视觉结果:一项系统评价
J Clin Med. 2025 Jan 28;14(3):871. doi: 10.3390/jcm14030871.
3
Exploring the Effect of Preoperative Stereopsis on Visual Outcomes in Hyperopic Presbyopes Treated with PresbyOND Laser Blended Vision Micro-Monovision.探讨术前立体视对接受PresbyOND激光混合视力微单眼视力治疗的远视性老花眼患者视觉效果的影响。
J Clin Med. 2023 Oct 7;12(19):6399. doi: 10.3390/jcm12196399.
4
Effectiveness of SMILE Combined with Micro-Monovision in Presbyopic Patients: A Pilot Study.飞秒激光小切口基质透镜切除术联合微单眼视矫正老花眼患者的有效性:一项初步研究。
Life (Basel). 2023 Mar 20;13(3):838. doi: 10.3390/life13030838.
5
Review of Presbyopia Treatment with Corneal Inlays and New Developments.角膜嵌体治疗老花眼的综述及新进展
Clin Ophthalmol. 2022 Aug 24;16:2781-2795. doi: 10.2147/OPTH.S375577. eCollection 2022.

本文引用的文献

1
Spherical aberration for expanding depth of focus.球差拓展景深。
J Cataract Refract Surg. 2021 Dec 1;47(12):1587-1595. doi: 10.1097/j.jcrs.0000000000000713.
2
Visual outcomes in hyperopic myopic and emmetropic patients with customized aspheric ablation (Q factor) and micro-monovision.远视、近视和正视患者接受定制非球面切削(Q 值)和微单视的视觉效果。
Int Ophthalmol. 2021 Jun;41(6):2179-2185. doi: 10.1007/s10792-021-01775-4. Epub 2021 Mar 16.
3
Clinical Effectiveness of Laser-Induced Increased Depth of Field for the Simultaneous Correction of Hyperopia and Presbyopia.激光诱导增加景深在远视和老视同时矫正中的临床效果。
J Refract Surg. 2021 Jan 1;37(1):16-24. doi: 10.3928/1081597X-20201013-03.
4
One Year Outcome and Satisfaction of Presbyopia Correction Using the PresbyMAX® Monocular Ablation Profile.使用PresbyMAX®单眼消融模式矫正老花眼的一年期结果及满意度
Front Med (Lausanne). 2020 Nov 27;7:589275. doi: 10.3389/fmed.2020.589275. eCollection 2020.
5
PresbyPRK vs presbyLASIK using the SUPRACOR algorithm and micromonovision in presbyopic hyperopic patients: visual and refractive results at 12 months.在老视性远视患者中使用SUPRACOR算法和微单眼视的准分子原位角膜磨镶术(PresbyPRK)与准分子激光原位角膜磨镶术(PresbyLASIK):12个月时的视觉和屈光结果
J Cataract Refract Surg. 2021 Jul 1;47(7):878-885. doi: 10.1097/j.jcrs.0000000000000544.
6
PresbyLASIK: A review of PresbyMAX, Supracor, and laser blended vision: Principles, planning, and outcomes.老视性准分子原位角膜磨镶术:PresbyMAX、Supracor及激光混合视力的综述:原理、规划与结果
Indian J Ophthalmol. 2020 Dec;68(12):2723-2731. doi: 10.4103/ijo.IJO_32_20.
7
Near visual acuity and patient-reported outcomes in presbyopic patients after bilateral multifocal aspheric laser in situ keratomileusis excimer laser surgery.双侧多焦点非球面准分子原位角膜磨镶术(LASIK)术后老花眼患者的近视力及患者报告结局
J Cataract Refract Surg. 2020 Jul;46(7):944-952. doi: 10.1097/j.jcrs.0000000000000198.
8
Objective optical quality and visual outcomes after the PresbyMAX monocular ablation profile.PresbyMAX单眼消融模式后的客观光学质量和视觉效果。
Int J Ophthalmol. 2020 Jul 18;13(7):1060-1065. doi: 10.18240/ijo.2020.07.07. eCollection 2020.
9
Visual and Refractive Outcomes Following Laser Blended Vision Using Non-linear Aspheric Micro-monovision.采用非线性非球面微单眼技术的激光混合视觉后的视力和屈光结果。
J Refract Surg. 2020 May 1;36(5):300-307. doi: 10.3928/1081597X-20200407-02.
10
One year results of presbyLASIK using hybrid bi-aspheric micro-monovision ablation profile in correction of presbyopia and myopic astigmatism.使用混合双非球面微单视消融模式的老视LASIK矫正老视和近视散光的一年结果
Int J Ophthalmol. 2020 Feb 18;13(2):271-277. doi: 10.18240/ijo.2020.02.11. eCollection 2020.

最新的老视矫正技术行准分子激光老视眼手术的临床疗效:系统评价。

Clinical outcomes of presbyopia correction with the latest techniques of presbyLASIK: a systematic review.

机构信息

Department of Ophthalmology (Qvision), VITHAS Hospital, Almería, Spain.

Department of Optics, Pharmacology and Anatomy, University of Alicante, Alicante, Spain.

出版信息

Eye (Lond). 2023 Mar;37(4):587-596. doi: 10.1038/s41433-022-02175-3. Epub 2022 Jul 21.

DOI:10.1038/s41433-022-02175-3
PMID:35864161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9998429/
Abstract

The aim of this study was to collect the scientific literature on the correction of presbyopia with laser in situ keratomileusis (presbyLASIK) in last years and to analyse the quality of such scientific evidence using a validated methodology for conducting a systematic review. A total of 42 articles were initially identified, but after applying the selection criteria and an additional manual search a total of 23 articles were finally included: 2 non-randomized controlled clinical trials (NRCT) and 21 case series. Quality assessment of NRCTs and case series was performed with the ROBINS-I and the 20-criterion quality appraisal checklist defined by Moga et al. (IHE Publ 2012), respectively. For NRCT, the risk of bias was moderate in one study and serious in the other NRCT, being the main sources of risk, the domains related to confounding, selection of participants and measurement of outcomes. For case series studies, the main source of risk of bias was subjects not entering the study at the same point of the conditions (different levels of presbyopia). Likewise, a significant level of uncertainty was detected for the following items: consecutive recruitment of patients, blinding of outcome assessors to the intervention that the patient received, and conclusions of the study not supported by the results. Research on presbyLASIK to this date is mainly focused on case series generating a limited level of scientific evidence. The two NRCTs identified only demonstrated the potential benefit of combining the multiaspheric profile with some level of monovision in the non-dominant eye.

摘要

本研究旨在收集近年来应用准分子激光原位角膜磨镶术(presbyLASIK)矫正老视的科学文献,并使用经过验证的系统评价方法分析此类科学证据的质量。最初共确定了 42 篇文章,但在应用选择标准和额外的手动搜索后,最终共纳入 23 篇文章:2 项非随机对照临床试验(NRCT)和 21 项病例系列研究。使用 ROBINS-I 和 Moga 等人定义的 20 项质量评估检查表(IHE Publ 2012)分别对 NRCT 和病例系列研究进行质量评估。对于 NRCT,一项研究的偏倚风险为中度,另一项 NRCT 的偏倚风险为严重,偏倚的主要来源是与混杂、参与者选择和结果测量相关的领域。对于病例系列研究,偏倚风险的主要来源是受试者在同一条件下(不同程度的老视)未进入研究。同样,对以下项目也检测到了显著的不确定性水平:患者连续招募、结局评估者对患者接受的干预措施保持盲法,以及研究结论与结果不一致。迄今为止,关于 presbyLASIK 的研究主要集中在生成科学证据水平有限的病例系列研究上。确定的两项 NRCT 仅证明了在非主导眼联合多球镜和一定程度的单视的潜在益处。